Better Buy in 2026: Pfizer or Eli Lilly?

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and growing their respective businesses for decades. But in recent years, it's been Eli Lilly that has been the dominant stock to own. Since 2023, it has risen by nearly 200%, while Pfizer has lost nearly half of its value.While it may be tempting to assume that the pattern will continue, it's also important to consider valuation and other factors that may impact future returns. Past returns are simply a reflection of how a business has done in the past, not how it will do in the years ahead. Below, I'll look at the growth opportunities, financial strength, and valuation of these healthcare stocks to assess which one may be the better buy heading into 2026.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool